We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Clinical Metagenomic Sequencing Improves Diagnosis of Neurological Infections

By LabMedica International staff writers
Posted on 26 Jun 2019
Metagenomic next-generation sequencing (NGS) is a promising approach for the diagnosis of infectious disease because a comprehensive spectrum of potential causes, viral, bacterial, fungal, and parasitic, can be identified by a single assay.

Diagnosis by traditional approached is particularly challenging for neuroinflammatory diseases given overlapping clinical manifestations of infectious and noninfectious causes, a lack of diagnostic tests for rare pathogens, and the limited availability and volume of central nervous system (CNS) samples owing to the requirement for invasive procedures, such as lumbar puncture or brain biopsy.

A group of scientists collaborating with the University of California, San Francisco (San Francisco, CA, USA) investigated the usefulness of metagenomic NGS of CSF for the diagnosis of infectious meningitis and encephalitis in hospitalized patients. More...
All positive tests for pathogens on metagenomic NGS were confirmed by orthogonal laboratory testing. The team enrolled 204 pediatric and adult patients at eight hospitals. Patients were severely ill: 48.5% had been admitted to the intensive care unit, and the 30-day mortality among all study patients was 11.3%. A total of 58 infections of the nervous system were diagnosed in 57 patients (27.9%).

RNA and DNA libraries that were generated from CSF samples obtained from patients were each sequenced to a depth of 5 million to 10 million single-end, 140-base-pair reads on an Illumina HiSeq instrument, in rapid-run mode. Among these 58 infections, metagenomic NGS identified 13 (22%) that were not identified by clinical testing at the source hospital. Among the remaining 45 infections (78%), metagenomic NGS made concurrent diagnoses in 19. Of the 26 infections not identified by metagenomic NGS, 11 were diagnosed by serologic testing only, seven were diagnosed from tissue samples other than CSF, and eight were negative on metagenomic NGS owing to low titers of pathogens in CSF. A total of 8/13 diagnoses made solely by metagenomic NGS had a likely clinical effect, with 7/13 guiding treatment.

Infections that were diagnosed solely by metagenomic NGS included St. Louis encephalitis virus (SLEV), hepatitis E virus, and Streptococcus agalactiae; these pathogens had not been considered by the treating clinicians for the patients. Metagenomic NGS also identified pathogens for which there was some degree of clinical suspicion, although conventional testing had returned negative (Neisseria, Nocardia farcinica, Candida tropicalis, Enterobacter aerogenes [now renamed Klebsiella aerogenes], S. mitis, and Enterococcus faecalis).

The authors concluded that clinical metagenomic NGS of CSF represents a potential step forward in the diagnosis of meningoencephalitis. This diagnostic approach may guide earlier and more targeted treatments for neuroinvasive infections, identify emerging infections and disease phenotypes, and accelerate the workup and treatment for noninfectious causes. The study was published on June 13, 2019, in The New England Journal of Medicine.

Related Links:
University of California, San Francisco


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.